Back to Home

Fulcrum Therapeutics

NASDAQ: FULC $3.83 USD~$0.3B MCAP

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies to modulate gene expression for genetically defined diseases including facioscapulohumeral muscular dystrophy (FSHD) and sickle cell disease.

Company Info

Sector:Rare disease / Genomics
Headquarters:Cambridge, Massachusetts, USA
Founded:2016

Recent News

No recent news updates available for this company.

Leadership Team

Careers & Job Openings

See all open roles

Various
USA
Apply Now